A same day α-synuclein RT-QuIC seed amplification assay for synucleinopathy biospecimens.

npj Biosensing Pub Date : 2025-01-01 Epub Date: 2025-02-11 DOI:10.1038/s44328-024-00023-w

Sabiha Parveen, Parvez Alam, Christina D Orrù, Sarah Vascellari, Andrew G Hughson, Wen-Quan Zou, Thomas G Beach, Geidy E Serrano, David S Goldstein, Bernardino Ghetti, Giovanni Cossu, Giada Pisano, Beatrice Pinna, Byron Caughey

{"title":"A same day α-synuclein RT-QuIC seed amplification assay for synucleinopathy biospecimens.","authors":"Sabiha Parveen, Parvez Alam, Christina D Orrù, Sarah Vascellari, Andrew G Hughson, Wen-Quan Zou, Thomas G Beach, Geidy E Serrano, David S Goldstein, Bernardino Ghetti, Giovanni Cossu, Giada Pisano, Beatrice Pinna, Byron Caughey","doi":"10.1038/s44328-024-00023-w","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD), dementia with Lewy bodies (DLB), and other synucleinopathies are characterized by the accumulation of abnormal, self-propagating aggregates of α-synuclein. RT-QuIC or seed amplification assays are currently showing unprecedented diagnostic sensitivities and specificities for synucleinopathies even in prodromal phases years in advance of the onset of Parkinsonian signs or dementia. However, commonly used α-synuclein seed amplification assays take ≥48 h to perform as applied to patients' diagnostic biospecimens. Here, we report the development of a faster α-synuclein RT-QuIC assay that is as analytically sensitive as prior assays of this type, but can be completed in ≤12 h for brain, skin, and intestinal mucosa, with positive signals often arising in <5 h. CSF assays took a few hours longer. Our same-day α-synuclein RT-QuIC (sdRT-QuIC) assay should increase the practicality, cost-effectiveness, and throughput of measurements of pathological forms of α-synuclein for fundamental research, clinical diagnosis, and therapeutics development.</p>","PeriodicalId":501705,"journal":{"name":"npj Biosensing","volume":"2 1","pages":"8"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813799/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Biosensing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s44328-024-00023-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Parkinson's disease (PD), dementia with Lewy bodies (DLB), and other synucleinopathies are characterized by the accumulation of abnormal, self-propagating aggregates of α-synuclein. RT-QuIC or seed amplification assays are currently showing unprecedented diagnostic sensitivities and specificities for synucleinopathies even in prodromal phases years in advance of the onset of Parkinsonian signs or dementia. However, commonly used α-synuclein seed amplification assays take ≥48 h to perform as applied to patients' diagnostic biospecimens. Here, we report the development of a faster α-synuclein RT-QuIC assay that is as analytically sensitive as prior assays of this type, but can be completed in ≤12 h for brain, skin, and intestinal mucosa, with positive signals often arising in <5 h. CSF assays took a few hours longer. Our same-day α-synuclein RT-QuIC (sdRT-QuIC) assay should increase the practicality, cost-effectiveness, and throughput of measurements of pathological forms of α-synuclein for fundamental research, clinical diagnosis, and therapeutics development.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

npj Biosensing

自引率

0.00%

发文量